Brief: Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial
02/04/2025 11:06
April 2 (Reuters) - Greenwich Lifesciences Inc GLSI.O: GREENWICH LIFESCIENCES ANNOUNCES POSITIVE IMMUNE RESPONSE DATA FROM FLAMINGO-01 PHASE III CLINICAL TRIAL Source text: ID:nGNX34hDCh Further company coverage: GLSI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio